Dashboard
Manage Tickers

KPTIKaryopharm Therapeutics Inc.

Nasdaq karyopharm.com


$ 1.12 $ -0.01 (-0.89 %)    

Wednesday, 22-May-2024 15:59:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 1.11
$ 1.14
$ 1.11 x 1,400
$ 1.12 x 2,200
$ 1.09 - $ 1.15
$ 0.62 - $ 2.67
1,061,039
na
128.15M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-17-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-04-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-15-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-13-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
05/09/2024 10:53:41

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...

karyopharm-announces-refinancing-transactions-148m-of-existing-convertible-notes-due-in-2025-to-be-exchanged-for-111m-of-new-convertible-notes-due-in-2029-and-warrants-issues-new-100m-senior-secured-term-loan-due-in-2028a
Karyopharm Announces Refinancing Transacti...
05/08/2024 11:39:20

karyopharm-therapeutics-reaffirms-2024-revenue-guidance-of-140m-160m-versus-consensus-of-14652m-including-us-xpovio-net-product-revenue-guidance-of-100m-120m
Karyopharm Therapeutics Reaffirms 2024 Rev...
05/08/2024 11:39:20

karyopharm-therapeutics-q1-2024-gaap-eps-032-beats-033-estimate-sales-33126m-miss-34473m-estimate
Karyopharm Therapeutics Q1 2024 GAAP EPS $...
05/08/2024 11:38:06

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate ...

karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-american-society-of-clinical-oncology-annual-meeting
Karyopharm Announces Presentations In Endo...
04/24/2024 20:42:32

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"...

onco360-selected-as-the-preferred-national-specialty-pharmacy-partner-for-karyopharms-product-xpovio-a-first-in-class-xpo-1-inhibitor
Onco360 Selected As The Preferred National...
03/13/2024 20:38:15

Onco360®, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Ka...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Karyo...
03/01/2024 12:10:52

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

karyopharm-sees-2024-total-revenue-140m-160m-vs-15202m-est
Karyopharm Sees 2024 Total Revenue $140M-$...
02/29/2024 12:31:56

karyopharm-therapeutics-q4-2023-gaap-eps-036-misses-030-estimate-sales-3375m-miss-3540m-estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $...
02/29/2024 12:31:15

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimat...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

karyopharm-therapeuticss-earnings-a-preview
Karyopharm Therapeutics's Earnings: A Preview
02/28/2024 19:01:25

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
02/06/2024 17:31:29

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
02/05/2024 17:31:04

watching-karyopharm-therapeutics-traders-circulate-analyst-comments-suggesting-with-the-mor-takeover-interest-a-larger-cancer-company-could-also-be-interested-in-acquiring-kpti-for-selinexor
Watching Karyopharm Therapeutics; Traders ...
02/05/2024 17:23:25

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/05/2024 13:06:14

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
01/31/2024 21:31:06

karyopharm-expects-preliminary-unaudited-full-year-2023-total-revenue-of-146m-vs-15003m-est-expects-prelim-q4-revenue-336m-vs-3764m-est
Karyopharm Expects Preliminary Unaudited F...
01/08/2024 13:59:15

karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-phase-1-study-of-selinexor-60mg-and-ruxolitinib-in-jak-inhibitor-jaki-nave-myelofibrosis-patients
Karyopharm Shares Data At ASH 2023 Showing...
12/11/2023 06:40:27

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggesti...

karyopharm-therapeutics-announced-the-presentation-of-updated-long-term-safety-efficacy-data-from-a-pre-specified-exploratory-subgroup-analysis-of-siendo-study-in-patients-with-advanced-or-recurrent-tp53-wild-type-endometrial-cancer
Karyopharm Therapeutics Announced The Pres...
11/06/2023 12:19:25

piper-sandler-maintains-overweight-on-karyopharm-therapeutics-lowers-price-target-to-5
Piper Sandler Maintains Overweight on Kary...
11/03/2023 21:16:24

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION